Innoviva, Inc. (INVA)
21.03
-0.04
(-0.19%)
USD |
NASDAQ |
Aug 24, 16:00
21.03
0.00 (0.00%)
After-Hours: 20:00
Innoviva Net Income (Quarterly) : -83.42M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -83.42M |
| March 31, 2026 | 186.60M |
| December 31, 2025 | 164.15M |
| September 30, 2025 | 89.91M |
| June 30, 2025 | 63.69M |
| March 31, 2025 | -46.58M |
| December 31, 2024 | 20.33M |
| September 30, 2024 | 1.213M |
| June 30, 2024 | -34.68M |
| March 31, 2024 | 36.53M |
| December 31, 2023 | 61.53M |
| September 30, 2023 | 82.05M |
| June 30, 2023 | 1.28M |
| March 31, 2023 | 34.86M |
| December 31, 2022 | -68.31M |
| September 30, 2022 | 229.35M |
| June 30, 2022 | 21.37M |
| March 31, 2022 | 37.86M |
| December 31, 2021 | 45.65M |
| September 30, 2021 | 102.65M |
| June 30, 2021 | 110.85M |
| March 31, 2021 | 109.70M |
| December 31, 2020 | 75.02M |
| September 30, 2020 | 41.62M |
| June 30, 2020 | 98.22M |
| Date | Value |
|---|---|
| March 31, 2020 | 78.95M |
| December 31, 2019 | 57.86M |
| September 30, 2019 | 47.05M |
| June 30, 2019 | 46.06M |
| March 31, 2019 | 40.02M |
| December 31, 2018 | 269.22M |
| September 30, 2018 | 50.17M |
| June 30, 2018 | 56.62M |
| March 31, 2018 | 30.33M |
| December 31, 2017 | 58.51M |
| September 30, 2017 | 23.77M |
| June 30, 2017 | 35.15M |
| March 31, 2017 | 16.84M |
| December 31, 2016 | 25.47M |
| September 30, 2016 | 15.03M |
| June 30, 2016 | 14.60M |
| March 31, 2016 | 4.435M |
| December 31, 2015 | 4.301M |
| September 30, 2015 | -4.584M |
| June 30, 2015 | -7.81M |
| March 31, 2015 | -10.67M |
| December 31, 2014 | -15.93M |
| September 30, 2014 | -21.27M |
| June 30, 2014 | -20.15M |
| March 31, 2014 | -67.70M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Zevra Therapeutics, Inc. | 8.393M |
| Collegium Pharmaceutical, Inc. | -15.05M |
| CorMedix, Inc. | 25.99M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 123.05M |
| Total Expenses (Quarterly) | 206.47M |
| EPS Diluted (Quarterly) | -1.136 |
| Enterprise Value | 1.218B |
| Gross Profit Margin (Quarterly) | 73.64% |
| Profit Margin (Quarterly) | -67.80% |
| Earnings Yield | 19.52% |
| Operating Earnings Yield | 9.41% |
| Normalized Earnings Yield | 10.87 |